会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明授权
    • Thieno-imino acid derivatives for use as matrix metalloproteinase inhibitors
    • 噻吩并亚氨基酸衍生物用作基质金属蛋白酶抑制剂
    • US07399770B2
    • 2008-07-15
    • US11461189
    • 2006-07-31
    • Manfred SchudokHans MatterArmin HofmeisterMaxime Lampilas
    • Manfred SchudokHans MatterArmin HofmeisterMaxime Lampilas
    • A61K31/4365C07D409/02C07D495/06
    • C07D495/04
    • The invention is directed to a compound of the formula I wherein the variables are as defined herein, or a stereoisomeric form thereof, mixture of stereoisomeric forms, in any ratio, or a salt thereof. Another aspect of the present invention is directed to a pharmaceutical composition comprising, a pharmaceutically effective amount of one or more compounds of formula I according to claim 1 in admixture with a pharmaceutically acceptable carrier.The invention is also directed to a method for effecting the prophylaxis and therapy of degenerative joint diseases such as osteoarthroses, spondyloses, cartilage loss following joint trauma or a relatively long period of joint immobilization following meniscus or patella injuries or ligament ruptures, diseases of the connective tissue such as collagenoses, periodontal diseases, wound healing disturbances and chronic diseases of the locomotory apparatus such as inflammatory, immunological or metabolism-associated acute and chronic arthritides, arthropathies, myalgias and disturbances of bone metabolism, for the treatment of ulceration, atheroscleroses and stenoses, and for the treatment of inflammations, cancer diseases, tumor metastasis formation, cachexia, anorexia, cardiac insufficiency and septic shock or for the prophylaxis of myocardial and cerebral infarctions, in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of the compound of formula I according to claim 1, or a pharmaceutically acceptable salt, solvate or prodrug thereof.Furthermore the invention is directed to a method for preparing a compound of formula I.
    • 本发明涉及式I化合物,其中变量如本文所定义,或其立体异构形式,立体异构体形式的任何比例的混合物或其盐。 本发明的另一方面涉及一种药物组合物,其包含药学有效量的一种或多种根据权利要求1的式I化合物与药学上可接受的载体的混合物。 本发明还涉及一种用于预防和治疗退行性关节疾病如骨关节炎,椎关节强硬,关节创伤后的软骨损失或半月板或髌骨损伤或韧带断裂后相对较长的关节固定的方法,连接性疾病 诸如胶原蛋白,牙周病,伤口愈合障碍和诸如炎症,免疫学或代谢相关的急性和慢性关节炎的关节病,关节病,肌痛和骨骼代谢紊乱的运动器官的组织,用于治疗溃疡,动脉粥样硬化和狭窄 ,并且用于在有需要的患者中治疗炎症,癌症疾病,肿瘤转移形成,恶病质,厌食症,心脏功能不全和败血性休克或用于预防心肌和脑梗死,包括向患者施用药学有效量 的compou 根据权利要求1的式I的或其药学上可接受的盐,溶剂合物或前药。 此外,本发明涉及制备式I化合物的方法。
    • 10. 发明授权
    • Factor VIIa inhibitors
    • 因子VIIa抑制剂
    • US06500803B1
    • 2002-12-31
    • US09588651
    • 2000-06-07
    • Otmar KlinglerManfred SchudokGerhard ZollerUwe HeineltElisabeth DefossaHans MatterPavel Safar
    • Otmar KlinglerManfred SchudokGerhard ZollerUwe HeineltElisabeth DefossaHans MatterPavel Safar
    • A61K3805
    • C07K5/06086A61K38/00
    • The present invention relates to compounds of formula I, in which R1, R2, R91, R92, R93, R94, R95, R96, R97, r, s, and t have the meanings indicated in the claims. Compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzyme factor VIIa and can in general be applied in conditions in which an undesired activity of factor VIIa is present or for the cure or prevention of conditions in which an inhibition of factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
    • 本发明涉及式Ⅰ化合物,其中R1,R2,R91,R92,R93,R94,R95,R96,R97,r,s和t具有权利要求中所示的含义。 式I化合物是有价值的药理活性化合物。 它们具有强烈的抗血栓形成作用,并且适用于例如治疗和预防血栓栓塞性疾病或再狭窄。 它们是血液凝固酶因子VIIa的可逆抑制剂,并且通常可以在其中存在不需要的因子VIIa活性的条件下或用于治疗或预防预期因子VIIa的抑制的病症。 本发明还涉及制备式I化合物的方法,其用途,特别是作为药物中的活性成分,以及包含它们的药物制剂。